DIUXF (Diaceutics) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DIUXF Diaceutics PLC DIUXF
80 GF Score
Price $2.00
GF Value $2.05
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Diaceutics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Diaceutics is: Low Risk: Strong fundamentals, worth long-term holding.

Diaceutics  (OTCPK:DIUXF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Diaceutics Risk Assessment Related Terms

DIUXF vs VEEV, BTSG, TEM: Risk Assessment Comparison

For the Health Information Services subindustry, Diaceutics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diaceutics Risk Assessment vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Diaceutics's Risk Assessment falls into.


DIUXF
80GF Score
Diaceutics PLC DIUXF
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Diaceutics (DIUXF) Overvalued in 2026?

Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued. The current stock price of $2.00 is trading 2.4% below its estimated GF Value™ of $2.05. GuruFocus considers Diaceutics to be Fairly Valued.

Key valuation signals for DIUXF:

  • Risk Assessment:
  • GF Value™: $2.05 vs. price of $2.00 (2.4% below fair value)
  • GF Score™: 80/100 with 1 warning sign

No single metric tells the full story. See the DIUXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diaceutics Business Description

Other Exchanges DXRX:UK7DC:Germany
Address Dataworks at Kings Hall Health & Wellbeing Park, First Floor, Building Two, County Antrim, Belfast, GBR, BT9 6GW
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
80GF Score

Get the complete analysis for DIUXF

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.00
Price
$2.05
GF Value